TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 08, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2022 and recent company developments,...
TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update
August 05, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 8, 2022 at 8:30 AM ET to discuss results for...
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
June 27, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II...
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
June 03, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations, including one oral and two poster presentations, highlighting data from...
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS
May 31, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
May 26, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and two poster presentations, highlighting...
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 20, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present virtually at...
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
April 26, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a...
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
April 15, 2022 08:30 ET
|
TG Therapeutics, Inc.
Company voluntarily withdraws UKONIQ® from sale for approved indications of relapsed/refractory MZL and FL Company to host conference call, Monday, April 18, 2022 at 8:30 AM ET NEW YORK, April 15,...
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
April 06, 2022 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with...